AKTX
Akari Therapeutics, Plc
Akari Therapeutics, Plc (AKTX) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 49.6, with 1/3 trend checks passing.
AKTX with MA50 and MA200
Key levels & signals
Akari Therapeutics, Plc (AKTX) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $12.07, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 9.2% and below the 200-day moving average by 15.0%.
AKTX currently has an RSI reading of 49.6, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
This page is designed to help you quickly understand what the AKTX chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Learn the indicators behind this page
More stock opportunities
Common questions about AKTX
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.